Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

McKesson
Express Scripts
McKinsey
Baxter
Johnson and Johnson
Merck

Last Updated: May 27, 2022

CLINICAL TRIALS PROFILE FOR REMDESIVIR


✉ Email this page to a colleague

« Back to Dashboard

505(b)(2) Clinical Trials for Remdesivir

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Dosage NCT05187793 ↗ Randomized Study of Efficacy of Different Treatment Regimens of Olokizumab Recruiting Federal Budget Institution of Science "Central Research Institute of Epidemiology" of the Rospotrebnadzor Phase 3 2021-07-08 The primary objective of the study is to evaluate the efficacy and safety of Artlegia (INN: olokizumab) new dosing regimen in patients with moderate coronavirus infection (COVID-19) with signs of hyperinflammation. This study is a multicentre, open-label, randomized, comparative, parallel group, active-controlled clinical trial.
New Dosage NCT05187793 ↗ Randomized Study of Efficacy of Different Treatment Regimens of Olokizumab Recruiting Group of companies Medsi, JS–° Phase 3 2021-07-08 The primary objective of the study is to evaluate the efficacy and safety of Artlegia (INN: olokizumab) new dosing regimen in patients with moderate coronavirus infection (COVID-19) with signs of hyperinflammation. This study is a multicentre, open-label, randomized, comparative, parallel group, active-controlled clinical trial.
New Dosage NCT05187793 ↗ Randomized Study of Efficacy of Different Treatment Regimens of Olokizumab Recruiting R-Pharm Phase 3 2021-07-08 The primary objective of the study is to evaluate the efficacy and safety of Artlegia (INN: olokizumab) new dosing regimen in patients with moderate coronavirus infection (COVID-19) with signs of hyperinflammation. This study is a multicentre, open-label, randomized, comparative, parallel group, active-controlled clinical trial.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Remdesivir

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03719586 ↗ Investigational Therapeutics for the Treatment of People With Ebola Virus Disease Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 2/Phase 3 2018-11-21 Background: Ebola virus can cause serious illness or death. No medicines are approved to treat it. Researchers need to test new medicines to see if they help people recover from Ebola and are safe to give. They need to test the drugs and compare them in a controlled way. Researchers want to test 4 drugs with people who have Ebola and are in treatment centers. Objective: To study the safety and effectiveness of 4 drugs for people with Ebola virus. Eligibility: People of any age with Ebola infection who are in treatment centers Design: Participants will be screened with questions, medical history, and blood tests. Participants will be randomly assigned to get 1 of 3 study drugs: - ZMapp by IV over about 4 hours. It will be given 3 times, 3 days apart. - Remdesivir by IV over about 1 hour. It will be given once a day for 10 days. - Mab114 by IV for 30-60 minutes. It will be given 1 time. - REGN-EB3 by IV for about 2 hours. It will be given 1 time. For at least a week, participants will stay in isolation in a clinic. They will: - Get supportive care and be monitored - Have a small plastic tube (IV) put in an arm vein for several days to give fluids and collect blood. - Get their study drug. - Be monitored for disease signs and drug side effects. They may get medicines for side effects. - Have blood and urine tests. Participants will stay in the clinic until they finish the study drug and are well enough to leave. Participants will have 2 follow-up visits over 2 months. They will answer questions and give blood and semen samples. ...
NCT04252664 ↗ A Trial of Remdesivir in Adults With Mild and Moderate COVID-19 Suspended Chinese Academy of Medical Sciences Phase 3 2020-02-12 In December 2019, Wuhan, in Hubei province, China, became the center of an outbreak of pneumonia of unknown cause. In a short time, Chinese scientists had shared the genome information of a novel coronavirus (SARS-CoV-2) from these pneumonia patients and developed a real-time reverse transcription PCR (real-time RT-PCR) diagnostic assay. Given no specific antiviral therapy for COVID-19 and the availability of remdesvir as a potential antiviral agent based on pre-clinical studies in SARS-CoV and MERS-CoV infections, this randomized, controlled, double blind trial will evaluate the efficacy and safety of remdesivir in patients hospitalized with mild or moderate COVID-19.
NCT04252664 ↗ A Trial of Remdesivir in Adults With Mild and Moderate COVID-19 Suspended Capital Medical University Phase 3 2020-02-12 In December 2019, Wuhan, in Hubei province, China, became the center of an outbreak of pneumonia of unknown cause. In a short time, Chinese scientists had shared the genome information of a novel coronavirus (SARS-CoV-2) from these pneumonia patients and developed a real-time reverse transcription PCR (real-time RT-PCR) diagnostic assay. Given no specific antiviral therapy for COVID-19 and the availability of remdesvir as a potential antiviral agent based on pre-clinical studies in SARS-CoV and MERS-CoV infections, this randomized, controlled, double blind trial will evaluate the efficacy and safety of remdesivir in patients hospitalized with mild or moderate COVID-19.
NCT04257656 ↗ A Trial of Remdesivir in Adults With Severe COVID-19 Terminated Capital Medical University Phase 3 2020-02-06 In December 2019, Wuhan, in Hubei province, China, became the center of an outbreak of pneumonia of unknown cause. In a short time, Chinese scientists had shared the genome information of a novel coronavirus (SARS-CoV-2) from these pneumonia patients and developed a real-time reverse transcription PCR (real-time RT-PCR) diagnostic assay. Given no specific antiviral therapy for COVID-19 and the ready availability of remdesvir as a potential antiviral agent, based on pre-clinical studies in SARS-CoV and MERS-CoV infections, this randomized, controlled, double blind trial will evaluate the efficacy and safety of remdesivir in patients hospitalized with severe COVID-19.
NCT04280705 ↗ Adaptive COVID-19 Treatment Trial (ACTT) Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 3 2020-02-21 This study is an adaptive, randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of novel therapeutic agents in hospitalized adults diagnosed with COVID-19. The study is a multicenter trial that will be conducted in up to approximately 100 sites globally. The study will compare different investigational therapeutic agents to a control arm. There will be interim monitoring to introduce new arms and allow early stopping for futility, efficacy, or safety. If one therapy proves to be efficacious, then this treatment may become the control arm for comparison(s) with new experimental treatment(s). Any such change would be accompanied by an updated sample size. Because background standards of supportive care may evolve/improve over time as more is learned about successful management of COVID-19, comparisons of safety and efficacy will be based on data from concurrently randomized subjects. An independent Data and Safety Monitoring Board (DSMB) will actively monitor interim data to make recommendations about early study closure or changes to study arms. To evaluate the clinical efficacy, as assessed by time to recovery, of different investigational therapeutics as compared to the control arm.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Remdesivir

Condition Name

Condition Name for Remdesivir
Intervention Trials
COVID-19 49
Covid19 42
Corona Virus Infection 7
COVID-19 Pneumonia 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Remdesivir
Intervention Trials
COVID-19 118
Coronavirus Infections 25
Severe Acute Respiratory Syndrome 16
Pneumonia 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Remdesivir

Trials by Country

Trials by Country for Remdesivir
Location Trials
United States 477
Spain 35
Brazil 22
United Kingdom 18
Mexico 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Remdesivir
Location Trials
California 25
Texas 23
New York 23
Massachusetts 20
North Carolina 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Remdesivir

Clinical Trial Phase

Clinical Trial Phase for Remdesivir
Clinical Trial Phase Trials
Phase 4 8
Phase 3 45
Phase 2/Phase 3 14
[disabled in preview] 46
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Remdesivir
Clinical Trial Phase Trials
Recruiting 47
Completed 35
Not yet recruiting 21
[disabled in preview] 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Remdesivir

Sponsor Name

Sponsor Name for Remdesivir
Sponsor Trials
National Institute of Allergy and Infectious Diseases (NIAID) 14
Gilead Sciences 8
National Heart, Lung, and Blood Institute (NHLBI) 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Remdesivir
Sponsor Trials
Other 257
Industry 48
NIH 21
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Moodys
AstraZeneca
McKesson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.